论文部分内容阅读
目的探讨噻托溴铵在慢性阻塞性肺疾病治疗中的价值。方法采取平行、对照、随机研究。将37例慢性阻塞性肺疾病患者随机分为两组,一为噻托溴铵组(病例组),一为常规治疗组(对照组),研究周期为4周。在治疗前1天,第4周末,分别作血气分析、肺功能,并通过Borg评分、6分钟步行试验(6MWT)、SGRQ对患者总体健康状况进行评价。结果治疗前后比较,病例组中,FEV1、FVC占预计值百分比、FEV1/FVC均明显增高(P<0.05);病例组PaO2明显改善(P<0.05),而PaCO2差异无统计学意义(P>0.05);病例组中,Borg评分、6分钟步行距离(6MWD)和SGRQ均明显改善(P<0.05)。在对照组中,这些参数没有明显的改变。两组间变化值比较,差异均有统计学意义。结论噻托溴铵能明显地改善慢性阻塞性肺疾病患者的肺功能和氧合,增加运动的耐受力,降低呼吸困难指数和提高生活质量,在慢性阻塞性肺疾病治疗中具有重要的价值。
Objective To investigate the value of tiotropium in the treatment of chronic obstructive pulmonary disease. Methods A parallel, controlled, randomized study was performed. Thirty-seven patients with chronic obstructive pulmonary disease were randomly divided into two groups, one was tiotropium group (case group), the other was routine treatment group (control group). The study period was 4 weeks. Blood gas analysis and pulmonary function were performed on the first day and the fourth week before treatment, and the overall health of the patients was evaluated by Borg score, 6-minute walk test (6MWT) and SGRQ. Results Before and after treatment, FEV1 and FVC accounted for the percentage of predicted value, FEV1 / FVC were significantly increased (P <0.05); PaO2 was significantly improved (P <0.05) and PaCO2 was not statistically significant (P> 0.05). In the case group, Borg score, 6MWD and SGRQ were significantly improved (P <0.05). In the control group, these parameters did not change significantly. Changes between the two groups, the differences were statistically significant. Conclusions Tiotropium bromide can significantly improve pulmonary function and oxygenation, increase exercise tolerance, reduce dyspnea index and improve quality of life in patients with chronic obstructive pulmonary disease, and is of great value in the treatment of chronic obstructive pulmonary disease .